ANN ARBOR, MICHIGAN, May 01, 2026
Esperion Therapeutics has announced a definitive agreement to be acquired by ARCHIMED in a transaction valued at up to $1.1 billion, including contingent milestone payments tied to future commercial performance. Under the terms of the agreement, Esperion shareholders will receive $3.16 per share in cash at closing, representing a 58% premium to the company’s prior closing price, along with the opportunity to receive up to $100 million in additional milestone-based payments. The acquisition reflects a strategic move to strengthen Esperion’s position in cardiometabolic and rare disease therapeutics, while enabling ARCHIMED to expand its footprint in the global biopharmaceutical sector.
Strategic Acquisition Accelerates Growth in Cardiometabolic Therapies
The transaction underscores a shared vision to advance innovative therapies targeting cardiovascular disease, which remains the leading cause of mortality worldwide. Esperion has established itself as a commercial-stage biopharmaceutical company, with a focus on developing non-statin therapies for lowering low-density lipoprotein cholesterol (LDL-C), including its marketed products NEXLETOL® and NEXLIZET®. These therapies address a significant unmet need for patients who are unable to achieve optimal cholesterol levels with traditional statin treatments.
By acquiring Esperion, ARCHIMED aims to leverage its deep healthcare investment expertise to support the company’s Vision 2040 strategy, enhancing its ability to expand market reach, optimize commercialization, and accelerate pipeline development. The deal also positions Esperion for long-term growth in primary care and cardiovascular markets, where demand for innovative lipid-lowering therapies continues to rise.
Financial Structure Supports Long-Term Value Creation
Advertisement
The acquisition structure combines immediate shareholder value with future growth potential, offering both upfront cash consideration and contingent value rights (CVRs) linked to product performance. The additional milestone payments are tied to U.S. net sales of Esperion’s key products, including bempedoic acid-based therapies and pipeline candidates such as ENBUMYST®, providing incentives aligned with commercial success and market expansion.
The transaction is expected to close in the third quarter of 2026, subject to shareholder approval and regulatory clearances, after which Esperion will become a privately held company and cease trading on the Nasdaq Stock Market. Financing for the deal will be supported by investment funds managed by Pharmakon Advisors, highlighting strong investor confidence in Esperion’s commercial and clinical potential. This financial model reflects a broader trend in biopharma M&A, where transactions are increasingly structured to balance risk, performance, and long-term value creation.
Strengthening Biopharma Innovation and Global Market Position
From a GxP perspective, the acquisition is expected to maintain strict adherence to Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) standards, ensuring continued product quality, regulatory compliance, and patient safety.
The integration of Esperion into ARCHIMED’s portfolio will enable enhanced operational efficiency and strategic investment in research and development, particularly in areas of cardiometabolic and rare disease innovation. As healthcare systems worldwide face increasing burdens from chronic cardiovascular conditions, the need for effective, accessible, and patient-centric therapies continues to grow.
This acquisition positions both companies to capitalize on emerging opportunities in precision medicine and global healthcare markets, while reinforcing their commitment to delivering innovative solutions that improve patient outcomes. By combining Esperion’s scientific expertise and commercial infrastructure with ARCHIMED’s financial and strategic capabilities, the transaction represents a significant step forward in advancing next-generation biopharmaceutical innovation and expanding access to life-saving therapies worldwide.
Source: Esperion Therapeutics press release
